These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21624085)

  • 1. Removal of doripenem during hemodialysis and the optimum dosing regimen for patients undergoing hemodialysis.
    Tanoue K; Nishi K; Kadowaki D; Hirata S
    Ther Apher Dial; 2011 Jun; 15(3):327-33. PubMed ID: 21624085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem.
    Bretonnière C; Jacqueline C; Caillon J; Guitton C; Le Mabecque V; Miégeville AF; Villers D; Potel G; Boutoille D
    J Antimicrob Chemother; 2010 Nov; 65(11):2423-7. PubMed ID: 20858688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis.
    Cirillo I; Vaccaro N; Redman R; Black PL; Kearns GL
    J Clin Pharmacol; 2012 Nov; 52(11):1645-53. PubMed ID: 22174436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penetration of doripenem into prostatic tissue following intravenous administration in prostatectomy patients.
    Yamada Y; Ikawa K; Nakamura K; Mitsui K; Narushima M; Hibi H; Ikeda K; Morikawa N; Honda N
    Int J Antimicrob Agents; 2010 May; 35(5):504-6. PubMed ID: 20188521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of doripenem dosing in patients with end-stage renal disease receiving hemodialysis.
    Heil EL; Daniels LM; Walko CM; Nicolau DP; Smith EA
    Ann Pharmacother; 2011 Nov; 45(11):1455-6. PubMed ID: 22009996
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics and monte carlo simulations of doripenem in patients with febrile neutropenia.
    Stein GE; Kulhanek G; Smith CL; Kuti JL; Nicolau DP; Scharmen A; Farnum C; Tran M; Kalra A; Havlichek DH
    Ann Pharmacother; 2012 Oct; 46(10):1281-6. PubMed ID: 23012385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination of Doripenem during Dialysis and Pharmacokinetic Evaluation of Posthemodialysis Dosing for Patients Undergoing Intermittent Renal Replacement Therapy.
    Vossen MG; Ehmann L; Pferschy S; Maier-Salamon A; Haidinger M; Weiser C; Wenisch JM; Saria K; Kajahn C; Jilch S; Lemmerer R; Bécède M; Zeitlinger M; Kloft C; Jäger W; Thalhammer F
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.
    Cirillo I; Vaccaro N; Turner K; Solanki B; Natarajan J; Redman R
    J Clin Pharmacol; 2009 Jul; 49(7):798-806. PubMed ID: 19553404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
    Roberts JA; Udy AA; Bulitta JB; Stuart J; Jarrett P; Starr T; Lassig-Smith M; Roberts NA; Dunlop R; Hayashi Y; Wallis SC; Lipman J
    J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic analysis of doripenem in elderly patients with nosocomial pneumonia.
    Harada M; Inui N; Suda T; Nakamura Y; Wajima T; Matsuo Y; Chida K
    Int J Antimicrob Agents; 2013 Aug; 42(2):149-54. PubMed ID: 23684002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
    Roberts JA; Lipman J
    Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges.
    Nalda-Molina R; Dokoumetzidis A; Charkoftaki G; Dimaraki E; Margetis K; Archontaki H; Markantonis S; Boutos N; Sakas D; Vryonis E; Skoutelis A; Valsami G
    J Antimicrob Chemother; 2012 Jul; 67(7):1722-9. PubMed ID: 22457313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.
    Bhalodi AA; Keel RA; Quintiliani R; Lodise TP; Nicolau DP; Kuti JL
    Ann Pharmacother; 2013 May; 47(5):617-27. PubMed ID: 23585647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation.
    Ikawa K; Morikawa N; Ikeda K; Ohge H; Sueda T
    Diagn Microbiol Infect Dis; 2008 Nov; 62(3):292-7. PubMed ID: 18703305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.
    Ikawa K; Morikawa N; Uehara S; Monden K; Yamada Y; Honda N; Kumon H
    Int J Antimicrob Agents; 2009 Mar; 33(3):276-9. PubMed ID: 19095418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doripenem Treatment during Continuous Renal Replacement Therapy.
    Vossen MG; Wenisch JM; Maier-Salamon A; Fritsch A; Saria K; Zuba C; Jilch S; Lemmerer R; Unger M; Jaehde U; Jäger W; Thalhammer F
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1687-94. PubMed ID: 26711775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of high-dose 4-hour infusion of doripenem, in combination with fosfomycin, for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia.
    Apisarnthanarak A; Mundy LM
    Clin Infect Dis; 2010 Dec; 51(11):1352-4. PubMed ID: 21050114
    [No Abstract]   [Full Text] [Related]  

  • 19. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.
    Kim A; Banevicius MA; Nicolau DP
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2497-502. PubMed ID: 18458125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.
    Asuphon O; Montakantikul P; Houngsaitong J; Kiratisin P; Sonthisombat P
    Int J Infect Dis; 2016 Sep; 50():23-9. PubMed ID: 27418581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.